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ABSTRACT 2 
Here we describe clinicopathologic features of EVD in pregnancy. One woman was infected 3 
with Sudan virus had stillbirth and survived in Gulu, Uganda in 2000, and a second woman with 4 
Bundibugyo virus had livebirth with maternal and infant death in Isiro, the Democratic Republic 5 
of Congo in 2012.  Ebolavirus antigen was seen in the syncytiotrophoblast and placental 6 
maternal mononuclear cells by immunohistochemistry, and no antigen was seen in fetal 7 
placental stromal cells, or in fetal organs. In the Gulu case, ebolavirus antigen localized to 8 
malaria pigment-laden macrophages. These data suggest trophoblast infection may be a 9 
mechanism of transplacental ebolavirus transmission.  10 
 11 
INTRODUCTION 12 
Ebola virus disease (EVD) and Marburg virus disease (MVD) are caused by viruses of the 13 
Ebolavirus and Marburgvirus genera (family Filoviridae). Here, we collectively refer to Ebola 14 
(EBOV), Sudan (SUDV) and Bundibugyo (BDBV) virus species (all within the Ebolavirus genus) as 15 
ebolaviruses. Filovirus infection during pregnancy is associated with maternal hemorrhage, pre-16 
term labor, miscarriage and maternal and neonatal death. Supplementary Table 1 presents a 17 
summary of literature to date on filovirus infection in pregnancy, which was also recently 18 
reviewed [1, 2]; of 119 cases reported in the scientific literature, maternal death was 85% and 19 
there was uniform loss of offspring, whether by miscarriage, stillbirth or neonatal death, 20 
including only 18 live births with the longest survival only 19 days of life [3].  21 
 22 
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With the exception of liver biopsies on patients with MVD in Marburg, Germany, in 1967 [4] 23 
and a biopsy to evaluate a periorbital mucormycete fungus coinfection in a patient who 24 
survived EVD in the Democratic Republic of the Congo (DRC) in 1995 [5], human pathological 25 
studies on patients with filovirus infection have been almost entirely limited to post-mortem 26 
samples at the end stage of disease [6], largely confined to skin punch biopsies and core needle 27 
biopsies of the liver and spleen. 28 
 29 
Despite the severity of filovirus infection in pregnancy for both mother and child, very little is 30 
known regarding pathogenesis. Fetal-placental viral tropism has been hypothesized due to 31 
recent observations during the 2013-2016 West Africa EBOV outbreak:  pregnant women were 32 
noted to survive EVD and clear virus from the blood without fetal loss during acute infection, 33 
and deliver stillbirths in the subsequent weeks and months with relatively high EBOV RNA levels 34 
in placental and fetal tissue swabs [7-9] [10]. We report clinical, histopathologic and 35 
immunohistochemical findings of SUDV and BDBV virus infections in two pregnant women and 36 
their offspring that help shed light on the pathogenesis of fetal infection and loss in EVD.  37 
 38 
METHODS 39 
Patients 40 
Two pregnant women with EVD were cared for in Ebola Treatment Centers (ETC) during 41 
ebolavirus outbreaks in Gulu, Uganda, in 2000 [11, 12] and Isiro, DRC in 2012 [13, 14].  42 
Specimens were collected and evaluated during the course of outbreak responses. 43 
 44 
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Ebolavirus diagnostic testing 45 
Enzyme-linked immunosorbent assays (ELISA)  and RT-PCR assays for SUDV in Gulu and RT-PCR 46 
assays for BDBV in Isiro were performed as previously described [15, 16] in field laboratories 47 
run by the Viral Special Pathogens Branch (VSPB), U.S. Centers for Disease Control and 48 
Prevention (CDC), Atlanta, GA.  BDBV IgM and IgG enzyme-linked immunosorbent assays (ELISA) 49 
were performed by VSPB, CDC, Atlanta, GA. 50 
 51 
Histopathology, immunohistochemistry and transmission electron microscopy  52 
Placenta (Gulu and Isiro), fetal tissues (Gulu) and a post-mortem skin biopsy (Isiro) were 53 
collected and placed in 10% neutral buffered formalin and transported to the CDC where the 54 
samples were processed using standard histological methods.  The identification and scoring of 55 
malaria pigment was performed as previously described [17].  Immunohistochemistry (IHC) for 56 
ebolavirus antigens was performed using a polymer-based indirect immunoalkaline 57 
phosphatase detection system for colorimetric detection (Biocare Medical, Concord, CA). 58 
Rabbit polyclonal antisera against EBOV, SUDV and Reston virus, and EBOV hyperimmune 59 
mouse ascitic fluid (courtesy Thomas Ksiazek, VSPB, CDC), previously shown to detect SUDV and 60 
BDBV antigens, were each used at a 1:1000 dilution with appropriate positive and negative 61 
controls [18].  On slide embedding and transmission electron microscopy was performed as 62 
previously described [19]. 63 
 64 
 65 
 66 
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RESULTS 67 
Patient #1: Case Presentation, Gulu, Uganda 68 
A 30 year-old housewife in Gulu District of northern Uganda who presented with asthenia, 69 
anorexia, abdominal pain, nausea and vomiting, non-bloody diarrhea, and dry cough for 1 day. 70 
She reported previous contact with other persons with EVD in her village. Based on the dates 71 
provided to her from previous antenatal clinic visits, she was 28 weeks pregnant but reported 72 
feeling no fetal movements in the past few days. Vital signs were not taken on admission due to 73 
minimal staffing but the next day her axillary temperature was 36.7°C, pulse 120 bpm, and 74 
respiratory rate 24 breaths per minute, with oxygen saturation on pulse oximetry of 92 percent. 75 
Physical exam revealed conjunctival injection, diffuse abdominal tenderness, and slight 76 
pulmonary rales. The patient was clearly pregnant, but no formal obstetric exam was 77 
performed. She was placed on intravenous fluids and oral amoxicillin. Her blood tested positive 78 
for SUDV by both ELISA antigen assay and nested RT-PCR. 79 
   80 
On day four of illness the patient spontaneously delivered a dead but apparently 81 
morphologically normal fetus and placenta. The degree of vaginal bleeding did not seem out of 82 
the ordinary for a stillbirth. Over the next three days, the patient complained of pain and 83 
swelling of the joints, especially the wrists and knees, throat and chest pain, persistent dry 84 
cough with dyspnea and, briefly, hiccups. Her wrists and knees were visibly swollen and tender 85 
to the touch and rales continued to be noted. She was consistently febrile during this time, with 86 
disease severity peaking at day 7 of illness, when her vital signs showed an axillary temperature 87 
of 37.8°C, pulse 128 bpm, respiratory rate 30 breaths per minute, and oxygen saturation of 90 88 
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percent. She gradually improved and she was discharged on day 13 with normal vital signs and 89 
all symptoms resolved. 90 
 91 
After the patient’s stillbirth, the medical staff explained to her in her native language that there 92 
was much to be learned about EVD in pregnant women, and that important knowledge could 93 
be gained by performing pathologic examination of the fetus and placenta. The patient agreed 94 
to submit those tissues for testing and written informed consent was obtained.  95 
 96 
Patient #1: Pathologic Findings, Gulu, Uganda 97 
The placenta had mild subchorionitis and a moderate amount of malaria pigment (hemozoin) in 98 
fibrin and within macrophages embedded in fibrin (Figure 1A). No parasitized erythrocytes or 99 
malarial intervillous inflammatory infiltrates were present. By electron microscopy, hemozoin 100 
crystallites were identified (Figure 1B), but no ebolavirus virions were seen.  The umbilical cord 101 
was normal.   102 
 103 
Immunohistochemistry revealed Ebolavirus antigen in the placenta, primarily within areas of 104 
fibrin deposition, localized to embedded maternal mononuclear cells including malaria 105 
pigment-laden macrophages (Figure 1C). Focal immunostaining was seen within the 106 
syncytiotrophoblast (Figure 1D). The decidua, fetal placental villous stroma, amnion and 107 
umbilical cord were negative by IHC and no tissue necrosis or viral inclusions were noted. 108 
 109 
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Fetal tissues (lung, heart, liver, spleen, kidney, skin, and bone marrow) were well-preserved 110 
with minimal autolysis, normal for gestational age and had no necrosis or viral inclusions.  All 111 
fetal tissues were negative by IHC. 112 
 113 
Patient #2: Case Presentation, Isiro, DRC 114 
Several clinical details have been previously published from this patient [13]. She was A 29 year-115 
old housewife, gravida-8 para-7, who was transferred from a health center because of suspicion 116 
of EVD by a local clinician who knew that her relative died recently. She was admitted to the 117 
ETC on day 4 of illness with fever, fatigue, headache, abdominal pain (with uterine 118 
contractions), anorexia, dysphagia, vomiting, diarrhea and muscle and joint pain.  The date of 119 
her last menstrual period was unknown but she was initially estimated to be 7 months 120 
pregnant.  Conjunctival injection was noted. Her heart rate was 80 bpm and respiratory rate 121 
20/min. Her cervix was 50% effaced with 4 cm dilation and fetal movement was normal. 122 
 123 
Before admission, she was treated with oral artemether-lumefantrine (AL), intravenous quinine, 124 
ampicillin, diazepam, cimetidine, and scopolamine. At the ETC, she was treated with oral 125 
rehydration and antibiotics (cefixime, presumably) and AL was continued. On the day of 126 
admission, she tested positive for BDBV by RT-PCR and ELISA IgM. On day 5 of illness her cervix 127 
was at 100% effacement and 8 cm dilation and she was treated with oxytocin. A malaria rapid 128 
diagnostic test was positive and AL was continued. That night (day 6 of illness), spontaneous 129 
vaginal delivery of a live-born male infant occurred without assistance. The degree of vaginal 130 
bleeding did not seem out of the ordinary for a normal delivery, although she had an episode of 131 
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black stool some hours later. She was treated with oxytocin, ergometrine, IV fluids, and 132 
cefixime, and Plumpy’nut was provided. On day 7 the mother rapidly deteriorated, with 133 
wheezing, drowsiness, weakness and a temperature of 38.5°C. Antibiotics were switched to 134 
ceftriaxone. The next day she became comatose and died.   A post mortem skin sample was 135 
taken from the mother as part of the routine outbreak response protocol [18]. 136 
 137 
The infant appeared healthy at birth, with Apgar scores of 8/10/10, and was clinically assessed 138 
to be at term based on examination of the nails and soles of the feet. Infant formula was 139 
provided, although the baby may have briefly breastfed immediately after delivery.  A placental 140 
sample was collected to evaluate for BDBV.  Blood collected at 1 day of age (the second day of 141 
life) was positive for BDBV by RT-PCR with a cycle threshold of 29.2. Over the next few days the 142 
baby was noted to be quiet and inactive. He became febrile (38.5°C) on day 4 of age and repeat 143 
testing of the blood revealed a cycle threshold on RT-PCR of 17.9 with negative ELISA for IgM 144 
and IgG. Over the next few days, the baby had hematemesis and bloody stools. He developed 145 
respiratory distress and coma and died on the seventh day of age (8th day of life).  No post 146 
mortem specimens were collected from the infant.  147 
 148 
Patient #2: Pathologic findings, Isiro, DRC 149 
In the placenta, scattered atypical maternal macrophages were seen within the intervillous 150 
space. These cells had degenerate appearing nuclei, cytoplasmic blebs and small eosinophilic 151 
cytoplasmic granules, suggestive of viral inclusions (Figure 2A). The placenta was otherwise 152 
normal, and the placental membranes and umbilical cord were not sampled.  No malaria 153 
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pigment or parasitized erythrocytes were seen. No virions were seen by transmission electron 154 
microscopy.  155 
 156 
Ebolavirus antigen was seen by IHC within the circulating large atypical maternal mononuclear 157 
cells (Figure 2B).  Antigen was also present in multiple foci within the villous 158 
syncytiotrophoblast (Figure 2C), frequently most intense at the basal aspect. Fetal stromal and 159 
endothelial cells were negative by IHC. In the basal plate, immunostaining was prominent 160 
within the extravillous trophoblast (Figure 2D) with scattered additional cell types likely 161 
representing decidual and maternal mononuclear cells. Focally, the lining cells of the maternal 162 
vessels of the basal plate (likely endovascular trophoblasts) were positive. Within the placenta, 163 
fetal stromal tissue, including villous blood vessels, was negative by IHC.  164 
 165 
The post-mortem maternal skin specimen was morphologically normal and IHC negative. 166 
 167 
DISCUSSION 168 
Vertical transmission of pathogens can be by transplacental, transvaginal or by breastfeeding 169 
routes. Placenta sampling provides the opportunity to study disease processes in living patients 170 
and gain insights regarding the mode and mechanism of vertical transmission. In this study, 171 
SUDV or BDBV antigen was noted in fetal trophoblast cells, suggesting that these viruses can 172 
infect, and potentially cross, the placental epithelial barrier, resulting in transplacental infection 173 
of the fetus. Transplacental infection of the fetus by EBOV has been previously documented in 174 
stillbirths by virus PCR analysis of amniotic fluid, fetal blood and fetal swab specimens [7, 8]. 175 
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The immuno-protective role of the placenta may promote the persistence of virus observed in 176 
these cases even after virus has been cleared from maternal blood [8, 9]. 177 
 178 
Several human pathogens can efficiently penetrate the placental barrier and infect the fetus, 179 
including some herpesviruses, HIV, Zika virus, Treponema and Toxoplasma. The trophoblast is 180 
the major cellular barrier to fetal infection, and is comprised of two major types: the villous 181 
trophoblast, which is directly exposed to maternal blood, and the extravillous trophoblast 182 
which invades the maternal decidua and directly contacts maternal cells, including lymphocytes 183 
and decidual stromal cells. In this study, both the syncytiotrophoblast (both patients) and the 184 
extravillous trophoblast (Isiro) demonstrated ebolavirus antigen by IHC (Supplementary figure).  185 
 186 
Findings from the two cases reported here together with the recent reports of EBOV RNA RT-187 
PCR-positive stillbirths in women who have recovered from EVD [7, 8] suggest ebolaviruses 188 
have a degree of placental tropism. Ebolavirus entry into cells involves endocytosis and 189 
macropinocytosis [20]—both mechanisms that are important for the placental acquisition of 190 
maternal nutrients for fetal growth [21]. The NPC1 gene, which is required for ebolavirus 191 
cellular infection [22], is expressed in the placental syncytiotrophoblast [23].  192 
 193 
Unexpectedly, fetal tissue from the Gulu patient showed no features of ebolavirus infection, 194 
suggesting that fetal demise was attributable to processes that occurred early in the course of 195 
maternal infection (e.g a systemic inflammatory response), which is consistent with the 196 
patient’s noting of lack of fetal movement in the days prior to presentation and delivery. Post-197 
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mortem tissue was not available from the baby of the Isiro patient, but he was BDBV RT-PCR 198 
positive by day 1 with a qualitative increase by day 4 of age, suggesting that the infant died of 199 
EVD. Although the finding of the IHC-positive trophoblast suggests potential transplacental 200 
BDBV transmission in the Isiro case, the baby appeared healthy at birth and fetal stromal tissue 201 
within the placenta was IHC-negative, so transvaginal infection cannot be excluded. 202 
Transplacental and transvaginal ebolavirus infection would not be mutually exclusive, such as in 203 
vertical transmission of HIV, in which one third is thought to be intrauterine-transplacental and 204 
the remainder transvaginal in the absence of preventative efforts [24].  205 
 206 
Identifying infections that occur near or at the time of delivery is particularly important because 207 
these may be suitable targets for prevention through procedural or chemotherapeutic 208 
interventions. The World Health Organization currently recommends that asymptomatic infants 209 
born to mothers with EVD be separated and formula-fed. However, if the infant is confirmed or 210 
suspected to be infected, the benefits of breast feeding are thought to outweigh the risks, and 211 
breast feeding is thus recommended if the mother is able [25]. 212 
 213 
The co-localization of malaria pigment and ebolavirus antigen in the placenta of the Gulu 214 
patient is a novel finding and suggests that these two pathogens may interact at a cellular level. 215 
Filoviruses target monocyte-macrophages, and monocyte-macrophage infiltrates are a hallmark 216 
of active placental Plasmodium falciparum infection.  Similar infiltrates are seen in other organs 217 
(particularly the liver and spleen) in non-pregnant individuals with severe malaria, further 218 
raising consideration of the potential for pathogen interaction. Of note, the Isiro patient had a 219 
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positive malaria rapid diagnostic test on her peripheral blood but no evidence of malaria-220 
related placental pathology, perhaps due to receiving antimalarial treatment with AL; up to one 221 
third of documented cases of antenatal malaria do not show evidence of malaria in the 222 
placenta [26].  223 
 224 
In contrast to the human infections described here, vertical transmission does not appear to 225 
occur in Egyptian fruit bats (Rousettus aegyptiacus), which are thought to be the natural 226 
reservoir of Marburg virus [27]; placentas of four naturally captured Marburg virus RNA-227 
positive Egyptian fruit bats were all PCR negative. This can perhaps be explained by recognition 228 
that zoonotic pathogens often have unique maintenance mechanisms in distinct hosts. The 229 
cellular structure of placentas is markedly diverse across mammalian species, including whether 230 
fetal trophoblasts are directly exposed to maternal blood. Such structural differences may 231 
influence the likelihood of pathogen vertical transmission and/or placental tropism in natural 232 
versus incidental hosts.  233 
 234 
Future sampling of placental tissue is necessary to fully understand the pathogenesis of EVD in 235 
pregnant women and their offspring and to ultimately develop ways to prevent or treat 236 
infection. In addition, given the very high rates of malaria in many areas where filovirus 237 
outbreaks occur and frequent EBOV-malaria co-infection during the 2013-2016 West African 238 
outbreak [28], future investigation of the interaction and clinical outcomes associated with 239 
these two pathogens should be a priority.   240 
 241 
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 327 
Figure 1: Placental findings from Patient #1. A) Hemozoin (malaria pigment) in fibrin 328 
(arrowheads), B) Transmission electron microscopy showing malaria hemozoin crystallites 329 
(arrowheads); no ebolavirus virions were identified. Scale bar=500 nm. C) Colocalization of 330 
ebolavirus antigen (arrowheads) with malaria pigment.  D) Serial sections by H&E (upper) and 331 
IHC (lower) showing ebolavirus antigen (arrowhead) localized to the syncytiotrophoblast.  332 
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 333 
 334 
Figure 2: Placental findings from Patient #2. A) Circulating atypical maternal macrophages with 335 
vacuolated cytoplasm and eosinophilic cytoplasmic granules suggestive of viral inclusions 336 
(arrowhead). By IHC, ebolavirus antigen localization to B) Circulating maternal macrophages; C) 337 
syncytiotrophoblast, D) intermediate trophoblast (arrowhead) within the basal plate. 338 
